Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol

• Published in: Clinical pharmacology in drug development Vol. 9; no. 5; pp. 629 - 638
• Main Authors: Tsai, Max, Case, Michael, Ardayfio, Paul, Hochstetler, Helen, Wilbraham, Darren
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2020; John Wiley and Sons Inc
• Subjects: Blood pressure; cardiovascular effects; Drug dosages; drug‐drug interaction; lasmiditan; Migraine; Oral administration; Original Manuscript; Pharmacokinetics; propranolol; vasoconstriction; migraine; lasmiditan; propranolol; pharmacokinetics; vasoconstriction; drug-drug interaction; cardiovascular effects

Lasmiditan (LY573144/COL‐144) is a high‐affinity, centrally penetrant, selective 5‐HT1F receptor agonist currently under investigation for acute treatment of migraine. Although lasmiditan is not known to induce vasoconstriction, it remains important to understand its effect on cardiovascular paramet...